HOME > BUSINESS
BUSINESS
- Asian Regenerative Medicine Associations Held 1st Symposium on Regulatory Harmonization in Tokyo
April 16, 2018
- Takeda CEO Eager to Lure More Partners to Shonan iPark, Says Diversity Is Source of Creativity
April 16, 2018
- Shonan Health Innovation Park Marks Grand Opening: Takeda
April 16, 2018
- Oncodesign Partners with Erytech to Support Preclinical Development of Anticancer Drugs
April 16, 2018
- Mylan Gets EU Rights for Fujifilm Kyowa Kirin Biologics’ Humira Biosimilar
April 12, 2018
- Chugai Drops Patent Suit over Nippon Kayaku’s Herceptin Biosimilar
April 12, 2018
- Japan Ethical Drug Sales Total 9.9 Trillion Yen in FY2017: Encise Snapshot
April 11, 2018
- Mitsubishi Tanabe’s ALS Drug Filing Accepted for Review in Canada
April 11, 2018
- Takeda Carve-Out Venture Boots Up with 250 Million Yen Seed Round
April 11, 2018
- Hisamitsu’s Japan Ethical Drug Sales Down 3.1% in FY2017
April 11, 2018
- Mitsubishi Tanabe Files with International Court for Upfront Payment Return from S. Korean Firm
April 11, 2018
- Osaka Univ. Spinout, Sumitomo Dainippon Strike Option Deal on Antibody-Inducing Peptides
April 10, 2018
- Otsuka Partners with Takara Bio to Codevelop Gene Therapy Products with Exclusive Sales Rights in Japan
April 10, 2018
- Ethical Drug Sales Up 1.0% in February: Crecon Report
April 9, 2018
- Kowa Gets High Court Backing in Livalo Patent Suit
April 9, 2018
- Alfresa to Fully Introduce Distribution Cost Analysis System; Will “Raise Reps’ Awareness of Importance of Price Negotiations”: Pres.
April 9, 2018
- Japan Generic Market Projected at 1.2 Trillion Yen in 2021: Fuji Keizai
April 6, 2018
- Takeda, DNDi to Collaborate in Visceral Leishmaniasis Drug Development
April 6, 2018
- Daiichi Sankyo Expands Cancer Collaboration with DarwinHealth
April 6, 2018
- Takeda to Divest Its Brazilian OTC, Gx Subsidiary to Local Pharma
April 6, 2018
ページ
In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…